Ovarian Cancer Recurrent Clinical Trial
Official title:
Trial of M4344 and Niraparib in Patients With PARP Resistant Recurrent Ovarian Cancer
The purpose of this study is to find out if a new drug, M4344, is safe and has beneficial effects when given in combination with the PARP inhibitor, Niraparib, in women with recurrent ovarian cancer that has progressed while on a PARP inhibitor.
The primary, secondary, and exploratory objective are to assess the safety of the combination of M4344 and Niraparib in a phase 1 trial of patients with PARP resistant recurrent ovarian cancer; to determine the response rate and percentage of participants who remain progression free survival (PFS) at 6 months (%PFS) among ovarian cancer participants that have become resistant to poly (adenosine diphosphate [ADP]) ribose polymerase inhibitors (PARPi) who are treated with ataxia telangiectasia and Rad3-related protein inhibitors (ATRi) + Niraparib in the dose expansion cohort; and to identify potential biological predictors of response and progression of disease with the combination of M4344 and Niraparib. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06014528 -
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
|
Phase 2 | |
| Recruiting |
NCT05001282 -
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03717610 -
Hyperthermic Intraperitoneal Chemotherapy for Treatment of Relapsed Ovarian Cancer
|
N/A | |
| Recruiting |
NCT04175470 -
Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer
|
Phase 2 | |
| Recruiting |
NCT03983226 -
Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)
|
Phase 2 | |
| Recruiting |
NCT05095558 -
Microtransplantation for Ovarian Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT03657966 -
DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06102707 -
The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients
|
N/A | |
| Terminated |
NCT03162562 -
The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer
|
Phase 1 | |
| Completed |
NCT01332656 -
Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
|
Phase 2 | |
| Completed |
NCT01111903 -
A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03734692 -
Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03827837 -
Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors
|
Phase 2 | |
| Not yet recruiting |
NCT05990192 -
SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy
|
Phase 2 | |
| Completed |
NCT01485848 -
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT03681548 -
A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.
|
Phase 1 | |
| Recruiting |
NCT04072263 -
Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer
|
Phase 1/Phase 2 |